Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CTSD | P07339 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23417659 | 0.93 | EPHX2 (0.68) | SIGMAR1EPHX2KMT2AMEN1EPHX1 | |
| SCHEMBL9029679 | 0.84 | SIGMAR1 (0.56) | SIGMAR1EPHX2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL9029674 | 0.84 | SIGMAR1 (0.56) | SIGMAR1EPHX2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL9028338 | 0.84 | GAA (0.60) | SIGMAR1EPHX2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2969801 | 0.84 | GAA (0.60) | SIGMAR1EPHX2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL13202133 | 0.84 | GAA (0.60) | SIGMAR1EPHX2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2969065 | 0.83 | SIGMAR1 (0.55) | SIGMAR1EPHX2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2978204 | 0.83 | TRPV1 (0.58) | SIGMAR1EPHX2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2978208 | 0.83 | TRPV1 (0.58) | SIGMAR1EPHX2SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL2969069 | 0.83 | SIGMAR1 (0.55) | SIGMAR1EPHX2SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
| EP-0852142-A1 | Diamines in the treatment of arrhythmia | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1998-07-08 | — | — | EP | disclosed |
| EP-0639973-A1 | DIAMINES IN THE TREATMENT OF ARRHYTHMIA | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993023024-A1 | DIAMINES IN THE TREATMENT OF ARRHYTHMIA | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | SIGMAR1 108/4885EPHX2 1117/4885KMT2A 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.